Jonathan Hopper - Dec 20, 2021 Form 4 Insider Report for Vericel Corp (VCEL)

Role
Chief Medical Officer
Signature
/s/ Sean Flynn, as Attorney-in-Fact for Jonathan Hopper
Stock symbol
VCEL
Transactions as of
Dec 20, 2021
Transactions value $
-$360,830
Form type
4
Date filed
12/22/2021, 05:54 PM
Previous filing
Jul 2, 2021
Next filing
Feb 8, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VCEL Common Stock Options Exercise $11K +1K +2.54% $10.95 40.4K Dec 20, 2021 Direct F1
transaction VCEL Common Stock Sale -$40K -1K -2.47% $40.00 39.4K Dec 20, 2021 Direct F1, F2
transaction VCEL Common Stock Options Exercise $98.6K +9K +22.83% $10.95 48.4K Dec 22, 2021 Direct F1
transaction VCEL Common Stock Sale -$361K -9K -18.58% $40.14 39.4K Dec 22, 2021 Direct F1, F2
transaction VCEL Common Stock Options Exercise $167K +10K +25.36% $16.66 49.4K Dec 22, 2021 Direct F1
transaction VCEL Common Stock Sale -$236K -5.88K -11.9% $40.08 43.5K Dec 22, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VCEL Stock Option (right to buy) Options Exercise $0 -1K -1.74% $0.00 56.6K Dec 20, 2021 Common Stock 1K $10.95 Direct F3
transaction VCEL Stock Option (right to buy) Options Exercise $0 -9K -15.9% $0.00 47.6K Dec 22, 2021 Common Stock 9K $10.95 Direct F3
transaction VCEL Stock Option (right to buy) Options Exercise $0 -10K -38.46% $0.00 16K Dec 22, 2021 Common Stock 10K $16.66 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2 The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2021.
F3 These options, representing the right to purchase 135,000 shares, became exercisable on August 20, 2019, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company.
F4 These options, representing the right to purchase a total of 26,000 shares, became exercisable in quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 6, 2019.